Adial Pharmaceuticals, Inc. (AZR) stock
AZRNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ADIL
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q/A on Oct 21, 2026Score 5/30
Share price
Not available yet
Price, market cap and P/E appear here once daily prices are connected.
Adial Pharmaceuticals shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Adial Pharmaceuticals's shares outstanding was 5M at Jun 30, 2026. For fiscal 2025 it was 1M, up 244.5% from the year before. The highest annual figure on record is 1M in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1M | +244.5% |
| FY2024 | Dec 31, 2024 | 0M | +240.5% |
| FY2023 | Dec 31, 2023 | 0M | +42.3% |
| FY2022 | Dec 31, 2022 | 0M | +34.7% |
| FY2021 | Dec 31, 2021 | 0M | +49.1% |
| FY2020 | Dec 31, 2020 | 0M | +26.5% |
| FY2019 | Dec 31, 2019 | 0M | +107.0% |
| FY2018 | Dec 31, 2018 | 0M | +2629.4% |
| FY2017 | Dec 31, 2017 | 0M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 5M | +987.7% |
| Q1 FY2026 | Mar 31, 2026 | 1M | +423.8% |
| Q4 FY2025 | Dec 31, 2025 | 1M | +326.3% |
| Q3 FY2025 | Sep 30, 2025 | 1M | +279.9% |
| Q2 FY2025 | Jun 30, 2025 | 0M | +154.0% |
| Q1 FY2025 | Mar 31, 2025 | 0M | +121.4% |
| Q4 FY2024 | Dec 31, 2024 | 0M | +174.8% |
| Q3 FY2024 | Sep 30, 2024 | 0M | +395.2% |
| Q2 FY2024 | Jun 30, 2024 | 0M | +269.7% |
| Q1 FY2024 | Mar 31, 2024 | 0M | +179.1% |
| Q4 FY2023 | Dec 31, 2023 | 0M | +126.8% |
| Q3 FY2023 | Sep 30, 2023 | 0M | +14.5% |
| Q2 FY2023 | Jun 30, 2023 | 0M | +16.3% |
| Q1 FY2023 | Mar 31, 2023 | 0M | +14.3% |
| Q4 FY2022 | Dec 31, 2022 | 0M | +24.0% |
| Q3 FY2022 | Sep 30, 2022 | 0M | +29.6% |
| Q2 FY2022 | Jun 30, 2022 | 0M | +38.2% |
| Q1 FY2022 | Mar 31, 2022 | 0M | +45.5% |
| Q4 FY2021 | Dec 31, 2021 | 0M | +44.4% |
| Q3 FY2021 | Sep 30, 2021 | 0M | +45.4% |
| Q2 FY2021 | Jun 30, 2021 | 0M | +55.8% |
| Q1 FY2021 | Mar 31, 2021 | 0M | +51.6% |
| Q4 FY2020 | Dec 31, 2020 | 0M | +35.5% |
| Q3 FY2020 | Sep 30, 2020 | 0M | +33.1% |
| Q2 FY2020 | Jun 30, 2020 | 0M | +10.4% |
| Q1 FY2020 | Mar 31, 2020 | 0M | +27.2% |
| Q4 FY2019 | Dec 31, 2019 | 0M | +59.8% |
| Q3 FY2019 | Sep 30, 2019 | 0M | +84.8% |
| Q2 FY2019 | Jun 30, 2019 | 0M | +187.4% |
| Q1 FY2019 | Mar 31, 2019 | 0M | +4631.5% |
| Q4 FY2018 | Dec 31, 2018 | 0M | +104.1% |
| Q3 FY2018 | Sep 30, 2018 | 0M | +69.8% |
| Q2 FY2018 | Jun 30, 2018 | 0M | +8.8% |
| Q1 FY2018 | Mar 31, 2018 | 0M | – |
| Q4 FY2017 | Dec 31, 2017 | 0M | – |
| Q3 FY2017 | Sep 30, 2017 | 0M | – |
| Q2 FY2017 | Jun 30, 2017 | 0M | – |